

IN THE CLAIMS:

Claims 1 through 27 and 29 through 47 are canceled herein without prejudice or disclaimer. Claim 27 has been amended herein. Pending claim 27 and proposed new claim 48 are presented herein. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

1-27. (Canceled).

28. (amended) A method for ~~the delivery of~~ delivering a nucleic acid of interest to a mesenchymal stem cell, said method comprising:

~~administering the nucleic acid delivery vehicle of claim 1, wherein said nucleic acid delivery vehicle comprises a fiber protein of adenovirus 16 or a functional part, derivative and/or analogue thereof~~ to the mesenchymal stem cells a recombinant adenovirus comprising the nucleic acid of interest and having a tissue tropism for mesenchymal stem cells, wherein said recombinant adenovirus's fiber comprises:

at least one protein fragment of an adenovirus serotype of subgroup C, and

at least a knob domain of a fiber protein of a second adenovirus serotype associated therewith,

wherein the second adenovirus serotype is selected from the group consisting of serotype 16, serotype 32, serotype 35, serotype 40-S, and serotype 51; and

infecting the mesenchymal stem cell with the recombinant adenovirus.

29-47. (Canceled).

48 (New) The method according to claim 28, wherein said adenovirus serotype of subgroup C is adenovirus serotype 5.